Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Just Biotherapeutics raises $14M

    Just Biotherapeutics Inc. (Seattle, Wash.) raised $14 million in a series A2 round. The Bill & Melinda Gates Foundation invested $8 million of the new money. Existing investors Merck & Co. Inc. (NYSE:MRK), Lilly Asia …

    Published on 7/25/2016
  • FINANCIAL NEWS: Niemann-Pick play Vtesse adds $17M to series A

    Vtesse Inc. (Gaithersburg, Md.) raised $17 million from insiders in an extension of its series A round, bringing the total to $42 million. Last year, Vtesse was spun out of Orphan drug accelerator Cydan Development Inc.…

    Published on 7/25/2016
  • FINANCIAL NEWS: Renal disease play Tricida raises $55M

    Tricida Inc. (South San Francisco, Calif.) raised $55 million in a series C round led by new investor Longitude Capital. New investor Vivo Capital also participated, as did existing investors OrbiMed, Sibling Capital …

    Published on 7/25/2016
  • FINANCIAL NEWS: Zixin takes majority stake in Nabsys

    Jilin Zixin Pharmaceutical Co. Ltd. (Shanghai:002118) will take a 67% stake in sequencing company Nabsys Inc. (Providence, R.I.) via a $42 million investment, according to a regulatory filing.Nabsys develops …

    Published on 7/25/2016
  • FINANCIAL NEWS: Alexandria buying One Kendall Square

    Alexandria Real Estate Equities Inc. (NYSE:ARE) is acquiring office complex One Kendall Square in Cambridge, Mass., for $725 million, according to a regulatory filing. The site is home to biotechs including Catabasis …

    Published on 7/21/2016
  • FINANCIAL NEWS: Financial tracks

    LSP's Joep Muijrers is relocating to the firm's Boston office in September. Muijrers, who was based in the Netherlands, will continue to invest in public EU and U.S. biotechs.

    Published on 7/21/2016
  • FINANCIAL NEWS: InflaRx raises EUR 31M in series C

    InflaRx GmbH (Jena, Germany) raised EUR 31 million ($34.3 million) in a series C round. New investors included Staidson Hongkong Investment Co. Ltd., international industrial investors and family offices. Existing …

    Published on 7/21/2016
  • FINANCIAL NEWS: Nextech closes Oncology Fund IV at $64M

    Nextech Invest Ltd. closed its Oncology Fund IV at $64 million. The fund, which had a $40 million first closing in October 2014, already has invested in three cancer biotechs: Peloton Therapeutics Inc. (Dallas, Texas), …

    Published on 7/20/2016
  • FINANCIAL NEWS: Strategics add to Akili's series B round

    In an extension of its series B round, Akili Interactive Labs Inc. (Boston, Mass.) raised $11.9 million from new investors Merck Ventures BV and Amgen Ventures, as well as existing investors. The extension brings the …

    Published on 7/20/2016
  • FINANCIAL NEWS: Synthetic biology play Synthorx raises $10M

    Synthorx Inc. (San Diego, Calif.) raised $10 million in a series B round led by new investor RA Capital. Existing investors Avalon Ventures and Correlation Ventures also participated. Synthorx is developing proteins …

    Published on 7/20/2016
  • FINANCIAL NEWS: Genexine raises W80M

    Genexine Inc. (KOSDAQ:095700) said it raised W80 million ($72 million) in equity and debt. The company raised W60 billion ($54 million) through the sale of convertible preferred stock to domestic investors including …

    Published on 7/19/2016
  • FINANCIAL NEWS: J&J hits all-time high on earnings news

    Johnson & Johnson (NYSE:JNJ) gained $2.11 to $125.25 on Tuesday, touching an intraday all-time high of $125.75, after it reported 2Q16 financial results that beat analyst estimates and raised its 2016 guidances. The …

    Published on 7/19/2016
  • FINANCIAL NEWS: Oncolytic virus play Oncorus raises $57M

    Oncorus Inc. (Cambridge, Mass.) debuted with $57 million in a series A round led by MPM Capital. Deerfield Management, Arkin Bio Ventures, Celgene Corp. (NASDAQ:CELG), Excelyrate Capital, and Long March Investment Fund …

    Published on 7/19/2016
  • FINANCIAL NEWS: Precision Ocular closes L15.5M round

    Precision Ocular Ltd. (Oxford, U.K.) closed its series A round with L15.5 million ($20.5 million) led by Imperial Innovations Group plc (LSE:IVO). Other investors include Consort Medical plc, NeoMed, V-Bio Ventures and …

    Published on 7/19/2016
  • FINANCIAL NEWS: Third Rock backs Fulcrum in $55M series A

    Third Rock Ventures launched Fulcrum Therapeutics Inc. (Cambridge, Mass.) and was the sole investor in the gene control company's $55 million series A financing. Fulcrum is developing small molecules that modulate …

    Published on 7/19/2016
  • FINANCIAL NEWS: Pharnext slips in first trading day

    Pharnext S.A.S. (Euronext:ALPHA) shed EUR 0.52 to EUR 10.30 in its first day of trading on Monday. Last week, the neurology company raised EUR 30.9 million ($34.1 million) in an IPO on Euronext Paris (see BioCentury …

    Published on 7/18/2016
  • FINANCIAL NEWS: Poxel raises EUR 26.5M

    Poxel S.A. (Euronext:POXEL) raised EUR 26.5 million ($29.3 million) in a private placement of 3.4 million shares at EUR 7.80 with U.S. and European institutional investors. Next year, Poxel intends to begin a Phase III …

    Published on 7/18/2016
  • FINANCIAL NEWS: Ardelyx raising $110M via private placement

    Ardelyx Inc. (NASDAQ:ARDX) gained $1.24 (14%) to $9.99 on Friday after it said it is raising $110 million through the sale of 12.6 million shares at $8.73 in a private placement. Investors include New Enterprise …

    Published on 7/15/2016
  • FINANCIAL NEWS: Hanmi launches venture arm

    Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) parent company Hanmi Pharmaceutical Group launched early stage investment arm Hanmi Ventures with W10 billion ($9 million).Hanmi Pharmaceutical Group Founder and Chairman …

    Published on 7/15/2016
  • FINANCIAL NEWS: MRC Technology sells Keytruda royalty rights for $150M

    MRC Technology (London, U.K.) sold a portion of its royalty rights to PD-1 inhibitor Keytruda pembrolizumab to DRI Capital for $150 million. Merck & Co. Inc. (NYSE:MRK) markets Keytruda to treat melanoma and non-small …

    Published on 7/15/2016
  • FINANCIAL NEWS: Kadmon updates IPO terms

    Kadmon Holdings LLC said it hopes to sell 5.6 million shares at $16-$20 in a planned IPO on NYSE. At the $18 midpoint, it would raise $100 million and have a postmoney valuation of $613.3 million. Underwriters are …

    Published on 7/14/2016
  • FINANCIAL NEWS: Flagship names Rosenblatt CMO

    Flagship Ventures hired Michael Rosenblatt as its first CMO. He had been EVP and CMO at Merck & Co. Inc. (NYSE:MRK) since 2009.Flagship said Rosenblatt will engage in the conception and launch of new companies. The firm…

    Published on 7/13/2016
  • FINANCIAL NEWS: GenSight raises EUR 40M in Euronext IPO

    Gene therapy company GenSight Biologics S.A. (Euronext:SIGHT) raised EUR 40 million ($44.1 million) through the sale of 5 million shares at EUR 8 in an IPO on Euronext Paris. The offering valued the company at about EUR…

    Published on 7/13/2016
  • FINANCIAL NEWS: GW raises $252M in follow-on

    GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH) raised $252 million through the sale of 2.8 million ADSs at $90 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Goldman Sachs, Cowen and Piper Jaffray. GW…

    Published on 7/13/2016
  • FINANCIAL NEWS: Pharnext listing brings in EUR 30.9M

    Pharnext S.A.S. (Euronext:ALPHA) raised EUR 30.9 million ($34.1 million) through the sale of 2.9 million shares at EUR 10.82 in an IPO on Euronext Paris. Gilbert Dupont is the underwriter. The offering valued Pharnext …

    Published on 7/13/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993